# A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

> **NCT07168200** · PHASE3 · RECRUITING · sponsor: **Shanghai Shengdi Pharmaceutical Co., Ltd** · enrollment: 720 (estimated)

## Conditions studied

- Advanced Cervical Cancer

## Interventions

- **DRUG:** SHR-1316 Injection
- **DRUG:** Cisplatin Injection
- **DRUG:** Carboplatin Injection
- **DRUG:** Paclitaxel Injection
- **DRUG:** SHR-1316 Placebo Injection

## Key facts

- **NCT ID:** NCT07168200
- **Lead sponsor:** Shanghai Shengdi Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-17
- **Primary completion:** 2028-04
- **Final completion:** 2028-12
- **Target enrollment:** 720 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07168200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07168200, "A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07168200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*